Skip to main content
. 2022 Apr 23;11(9):2363. doi: 10.3390/jcm11092363

Figure 2.

Figure 2

Relationship between PCI, QoL, and pharmacological group 4 (doxorubicin–cyclophosphamide–docetaxel).